Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) Soars 39% But It's A Story Of Risk Vs Reward

Despite an already strong run, Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370) shares have been powering on, with a gain of 39% in the last thirty days. The last 30 days bring the annual gain to a very sharp 26%.

Even after such a large jump in price, Jin Yang Pharmaceutical's price-to-earnings (or "P/E") ratio of 3.2x might still make it look like a strong buy right now compared to the market in Korea, where around half of the companies have P/E ratios above 12x and even P/E's above 24x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/E.

Recent times have been quite advantageous for Jin Yang Pharmaceutical as its earnings have been rising very briskly. One possibility is that the P/E is low because investors think this strong earnings growth might actually underperform the broader market in the near future. If that doesn't eventuate, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

View our latest analysis for Jin Yang Pharmaceutical

Want the full picture on earnings, revenue and cash flow for the company? Then our free report on Jin Yang Pharmaceutical will help you shine a light on its historical performance.

Is There Any Growth For Jin Yang Pharmaceutical?

There's an inherent assumption that a company should far underperform the market for P/E ratios like Jin Yang Pharmaceutical's to be considered reasonable.

If we review the last year of earnings growth, the company posted a terrific increase of 116%. The latest three year period has also seen an excellent 150% overall rise in EPS, aided by its short-term performance. Therefore, it's fair to say the earnings growth recently has been superb for the company.

Comparing that to the market, which is predicted to deliver 34% growth in the next 12 months, the company's momentum is pretty similar based on recent medium-term annualised earnings results.

In light of this, it's peculiar that Jin Yang Pharmaceutical's P/E sits below the majority of other companies. It may be that most investors are not convinced the company can maintain recent growth rates.

The Key Takeaway

Even after such a strong price move, Jin Yang Pharmaceutical's P/E still trails the rest of the market significantly. Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

Our examination of Jin Yang Pharmaceutical revealed its three-year earnings trends aren't contributing to its P/E as much as we would have predicted, given they look similar to current market expectations. There could be some unobserved threats to earnings preventing the P/E ratio from matching the company's performance. It appears some are indeed anticipating earnings instability, because the persistence of these recent medium-term conditions should normally provide more support to the share price.

You should always think about risks. Case in point, we've spotted 5 warning signs for Jin Yang Pharmaceutical you should be aware of, and 2 of them don't sit too well with us.

If these risks are making you reconsider your opinion on Jin Yang Pharmaceutical, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.